Vidhya Murthy

Consultant Haematologist with an interest in myeloid malignancies.

[Benlazar S M A @smbenlazar]

CPX-351 VERSUS STANDARD OF CARE AS BRIDGING TO ALLOHCT IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS OR OLIGOBLASTIC ACUTE MYELOID LEUKEMIA: RESULTS OF THE RANDOMIZED PHASE 2 PALOMA STUDY..
EHA Library; Jun 12 2026; 4206724
https://t.co/50isLuRjrT #EHA26 #mds

[Alex Rampotas @ARampotas]

Excited to share our new paper in @BrJHaem , led with @DrLornan on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group 🧵
Real-world treatment patterns & outcomes in accelerated and blast-phase MPNs — the largest UK cohort to date.
👇 https://t.co/ixUnooQuJW

[Bread & Butter Haematology @MorphologyAmigo]

Conferences are great for CPD- much of what we hear isn’t immediately usable in our system.

Let experts distil it down😀
👇Join the brilliant @Paneeshas @VidhyaMurthy1 & others
I learnt a lot from both
Maybe they teach you a thing or two :)
#medicine #hematology #medtwitter

[Vidhya Murthy @VidhyaMurthy1]

AML@ relapse. Revised prognostic model https://t.co/b64Stvo0WQ

[Vidhya Murthy @VidhyaMurthy1]

Great talk Gillian @horne_gillian. Fabulous 7th academy. Thanks to the organisers for putting together a fantastic programme @CoplandMhairi @charliecraddock Steve Knapper, Mike Dennis and Victoria Potter.

[Gillian Horne @horne_gillian]

What a brilliant #AMLAcademy this year! I am so inspired. Thanks to the organisers and @HT_Medical for allowing me to discuss #TYA with AML and the complexities often involved in their care.

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

We report incidence of NPM1-wildtype relapses in pts treated with VEN-based frontline tx in AML. 
 🔴Overall, absolute # of relapses in NPM1 AML after VEN is ⬇️
 🔴the fraction of NPM1-wildtype relapses ⬆️ with the⬆️ intensity of chemo backbone added to VEN.
 🔴 NPM1 wildtype relapses occur later and often had MR mutations.  And ALL (8/8) had a different flow immunophenotype compared to original AML.
 🔴We proposed that these were ‘new’ AMLs, that arose from common preleukemic (CH) precursor, but that the original NPM1-mutated AML was ‘cured’.

https://t.co/MTYuZEW15S
@AjHematology

[British Journal of Haematology @BrJHaem]

Peripheral cell morphological alterations may signal early dysplastic shifts. In the Lifelines cohort, a high RDW links to high-risk mutational patterns in CH and stratifies the risk of death in CCUS
https://t.co/tjGmoIiBjD
@lifelinesnl
@umcg

[Mostafa Faisal @MostafaFaisal14]

Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation
https://t.co/GmJD6H6hl1

[William Aird @WilliamAird4]

1/4

SERUM FERRITIN

Regulated at two levels:

✅ Cytokines (transcriptional control)
✅ Iron levels (translational control)

[Chethan Kumar @Chethan_Dash]

#Space #Update

On a cold, wind-brushed outpost at 14,000 ft in Ladakh, 2 #analogue crew will begin living in isolation to simulate physiological & psychological effects of a space mission as part of @isro experiment starting today. Facility built by a Bengaluru firm. 1/n

[ISRO @isro]

GSLV-F16/NISAR

From a majestic liftoff to the flawless separation, witness the full journey.

Watch spectacular moments of NISAR launching aboard GSLV-F16 and its precise separation, captured on-board.

A milestone in global space collaboration.

#ISRO #NASA #GSLVF16 #NISAR

[Dr. Chokri Ben Lamine @abouabdrahman0]

🔥 2025 ELN CML MANAGEMENT UPDATE 🔥

📌 Diagnosis 🧬
•Mandatory detection of BCR::ABL1 via CBA, FISH, RT-PCR.
•NGS recommended in blast phase (BP), not routine in chronic phase.
•ASXL1 mutations 🔬 → adverse prognostic marker in CP.
•Transcript type (e13a2 vs e14a2) may influence depth of response, but no therapeutic decision change yet.

📌 Disease Classification 🩸
•WHO 2022: CML is now biphasic:
•Chronic Phase (CP) <20% blasts.
•Blast Phase (BP) ≥20% blasts.
•Accelerated phase concept omitted but still acknowledged for risk stratification.

📌 Prognosis 🔎
•ELTS score replaces older prognostic models to predict CML-specific mortality ➡️
ELTS Calculator

📌 Monitoring 🧪
•Blood counts every 2 weeks until CHR.
•BCR::ABL1 PCR IS scale every 3 months until MMR, then q4-6 months.
•Use RT-qPCR or ddPCR.
•Monitoring definitions:
•MR4: ≤0.01%
•MR4.5: ≤0.0032%
•MR5: ≤0.001%

📌 Treatment Milestones 🛣️

TimeBCR::ABL1 ISAction
3mo≤10%Favorable
6mo≤1%Favorable
12mo≤0.1%Favorable

🔺 Unfavorable: >10% @3mo, >1% @12mo → switch TKI if confirmed.

📌 Mutation Testing 🧬
•Indicated for:
•TKI resistance
•Progression to BP
•Relapse post-alloSCT
•NGS preferred, Sanger acceptable.
•ddPCR can track specific mutations.

📌 First-Line Therapy 💊
•Asciminib: Now FDA-approved 1st line (ASC4FIRST trial): superior MMR vs imatinib/2G TKI with less toxicity.
•Imatinib, dasatinib, nilotinib, bosutinib remain standards.
•Dosing explorations:
•Dasatinib: 50mg daily shows reduced pleural effusion.
•Bosutinib: Titration from 100mg to 400mg recommended to limit GI toxicity.

📌 Second-Line & Beyond 🔄
•Switch TKI based on mutation profile:
•e.g. T315I → Ponatinib or Asciminib.
•Ponatinib dosing per OPTIC trial: Start 45mg, taper to 15mg once BCR::ABL1 IS <1%.

📌 Allo-SCT 🧬
•Reserved for:
•Resistance to ≥2 TKIs.
•BP or advanced phase.
•Early donor search in 2GTKI resistance.

📌 Treatment Free Remission (TFR) ✅
•Criteria:
•≥3 years on TKI.
•≥1 year sustained DMR.
•Euro-SKI: ~46% maintain TFR at 12mo.
•DESTINY trial: TKI dose reduction before stopping improves TFR rates.

📌 Practical Tips & Pearls 💡
•Always confirm PCR trends before switching TKIs.
•Tailor TKI choice to comorbidities:
•Pulmonary disease: ❌ Dasatinib.
•Diabetes/vascular risk: ❌ Nilotinib.
•Monitor and address compliance before declaring resistance.
•Involve transplant teams early if high-risk mutations/ACA.

📌 Exam Pearls 📝
•Most common BCR::ABL1 mutations → T315I, E255K/V, F359V/I/C.
•ELTS score >2: high risk.
•MR4.5 defines deep molecular response for TFR.

📚 Reference
Apperley JF, et al. 2025 European LeukemiaNet recommendations for the management of CML. Leukemia. 2025. Link

#CML #Leukemia #Hematology #ELN2025 #TFR #Asciminib #BCRABL1 #HemeOnc

[Jerome HADJADJ @HadjadjJerome]

Disease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies

https://t.co/qiA8UAuvOq

[paresh vyas @pvyas_oxford]

Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome https://t.co/Ou8qIVQrSx

10 year project with Irene Roberts and numerous collaborators. Natural history of myeloid preleukaemia and leukaemia in newborns and young children with T21.

[Marco Raddi @le_markg]

It’s finally out in Blood!!
A new molecular scoring system improving ESA response prediction in LR-MDS (ESA-PSS-M).
Check it out! Thanks to all the collaborators
#precisionmedicine #MDS

https://t.co/azzYqru0sI

[Kiran Mazumdar-Shaw @kiranshaw]

South India’s longest-know Car-T therapy survivors in Bengaluru return to daily life | Bengaluru News - this is amazing news ⁦@Immuneel_⁩ is really delivering on its promise of curing incurable cancers. So proud to hear these heart warming stories. https://t.co/P5x8lgxGkB

[Rabi Hanna @RabiHannaMD]

#regenerative medicine in type 1 DM:
#Stem cell–derived islets (zimislecel) infusion in portal vein restored islet function @NEJM
Outcomes in 14 patients
-All patients had detectable C-peptide
-100% reached HbA1c &lt;7%
-83% became insulin-independent
https://t.co/h0CYjBfW5b

[Uriel Suárez @UsuarezMD]

Intermediate-Dose Cytarabine as Postinduction AML Therapy | NEJM Evidence https://t.co/l3wXJXfh54

[Mostafa Faisal @MostafaFaisal14]

Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory AML (2013–2022): A retrospective study by the adult AML working group of the Japanese Society for Transplantation and Cellular Therapy @BrJHaem https://t.co/qbWNZib1cC

[Vidhya Murthy @VidhyaMurthy1]

Disappointing. Subgroup analysis will be key.

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. https://t.co/DlDzq32mn0